- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05086276
FX-322 in Adults With Acquired Sensorineural Hearing Loss
A Phase 2, Prospective, Randomized, Double-Blind, Placebo-Controlled, Single-Dose, Multicenter Study to Evaluate the Efficacy of FX-322 Administered by Intratympanic Injection in Adults With Acquired Sensorineural Hearing Loss
Study Overview
Status
Intervention / Treatment
Detailed Description
This is a Phase 2, prospective, randomized, double-blind, placebo-controlled, single-dose, multicenter study to evaluate the efficacy of FX-322, administered by intratympanic injection, in adults with acquired sensorineural hearing loss (SNHL).
Previous human studies in subjects 18 to 65 years inclusive (FX-322-103, FX-322-201, FX-322-111) and subjects 66-85 inclusive (FX-322-112) demonstrated that a single dose FX-322 was well tolerated in patients with acquired SNHL with no treatment-related serious adverse events. Adverse events in these studies were generally common to and associated with the intratympanic injection procedure with mild and transient discomfort in patients both with the drug and the placebo.
Frequency Therapeutics' Investigators intend to evaluate efficacy with a single dose of FX-322 in subjects 18 to 65 years inclusive with acquired SNHL.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Arizona
-
Tucson, Arizona, United States, 00000
- Clinical Trial Site
-
-
California
-
Fresno, California, United States, 00000
- Clinical Trial Site
-
Torrance, California, United States, 00000
- Clinical Trial Site
-
-
Colorado
-
Colorado Springs, Colorado, United States, 00000
- Clinical Trial Site
-
-
Florida
-
Sarasota, Florida, United States, 00000
- Clinical Trial Site
-
Tampa, Florida, United States, 00000
- Clinical Trial Site
-
-
Louisiana
-
Marrero, Louisiana, United States, 00000
- Clinical Trial Site
-
-
Michigan
-
Novi, Michigan, United States, 00000
- Clinical Trial Site
-
-
Nebraska
-
Omaha, Nebraska, United States, 00000
- Clinical Trial Site
-
-
New York
-
Albany, New York, United States, 00000
- Clinical Trial Site
-
Amherst, New York, United States, 00000
- Clinical Trial Site
-
New York, New York, United States, 00000
- Clinical Trial Site
-
-
North Carolina
-
Winston-Salem, North Carolina, United States, 00000
- Clinical Trial Site
-
-
Ohio
-
Cincinnati, Ohio, United States, 00000
- Clinical Trial Site
-
-
Oklahoma
-
Oklahoma City, Oklahoma, United States, 00000
- Clinical Trial Site
-
-
South Carolina
-
Charleston, South Carolina, United States, 00000
- Clinical Trial Site
-
Orangeburg, South Carolina, United States, 00000
- Clinical Trial Site
-
Spartanburg, South Carolina, United States, 00000
- Clinical Trial Site
-
-
Texas
-
Dallas, Texas, United States, 00000
- Clinical Trial Site
-
Fort Worth, Texas, United States, 00000
- Clinical Trial Site
-
San Antonio, Texas, United States, 00000
- Clinical Trial Site
-
-
Utah
-
Murray, Utah, United States, 00000
- Clinical Trial Site
-
Saint George, Utah, United States, 00000
- Clinical Trial Site
-
-
Virginia
-
Norfolk, Virginia, United States, 00000
- Clinical Trial Site
-
Richmond, Virginia, United States, 00000
- Clinical Trial Site
-
-
Wisconsin
-
Milwaukee, Wisconsin, United States, 00000
- Clinical Trial Site
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Subject has read and voluntarily signed the Informed Consent Form (ICF) after all questions have been answered and prior to any study-mandated procedure.
- Adult aged 18-65 years inclusive at Screening.
- Documented medical history consistent with acquired, adult onset, sensorineural hearing loss associated with noise-induced SNHL (NIHL) or idiopathic sudden SNHL (SSNHL) (documented audiogram at least 6 months prior to screening required).
- A pure tone average at the Screening Visit of 35-85 dB at 500Hz, 1000Hz, 2000Hz, and 4000Hz in the ear to be injected.
- Ability to communicate well with the Investigator and is willing to comply with and complete all the study procedures.
- Female subjects must be of non-childbearing potential or will need to utilize two methods of highly effective contraception during the study participation (e.g. hormonal contraception and condom or an intrauterine device and condom) or remain abstinent. Male subjects should use condoms with spermicide during the course of the study or remain abstinent. Subjects should not donate sperm or ova during the study period.
- Have met additional masked criteria as determined by the Electronic Data Capture system.
Exclusion Criteria:
- Subject has previously been randomized in a FX-322 clinical trial.
- Perforation of tympanic membrane or other tympanic membrane disorders that would interfere with the delivery and safety assessment of an intratympanic medication or reasonably be suspected to affect tympanic membrane healing after injection in study ear. This includes a current tympanostomy tube.
- Any conductive hearing loss of greater than 15 dB at a single frequency or greater than 10dB at two or more contiguous octave frequencies in the study ear at the Screening visit.
- Active chronic middle ear disease or a history of major middle ear surgery, as an adult, in the ear to be injected.
- Subject has had an intratympanic injection in either ear within 3 months of the screening visit.
- Evidence of or previous diagnosis of auditory neuropathy, traumatic brain injury, "central" hearing loss, or genetic hearing loss.
- History of chronic, recurrent clinically significant vestibular symptoms.
- History of bilateral sudden sensorineural hearing loss or recurrent sudden sensorineural hearing loss.
- History of clinically significant systemic autoimmune disease (e.g. rheumatoid arthritis, Sjogren's syndrome, multiple sclerosis, psoriasis).
- History of head or neck radiation, treatment, or exposure to platinum based chemotherapy drugs or aminoglycosides.
- Exposure to another investigational drug within 28 days prior to screening visit.
- Evidence of any active or chronic disease or condition that could interfere with, or for which the treatment of might interfere with, the conduct of the study, or that would pose an unacceptable risk to the subject in the opinion of the investigator following a detailed medical history, physical examination, and vital signs (systolic and diastolic blood pressure, pulse rate, body temperature).
- Positive urine pregnancy test or breast-feeding.
- Any known factor, condition, or disease that, in the view of the Investigator, might interfere with treatment compliance, study conduct or interpretation of the results.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: FX-322
FX-322, 1 dose
|
Active Comparator
|
Placebo Comparator: Placebo
Placebo, 1 dose
|
Placebo
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Word Recognition in Quiet
Time Frame: Baseline through Day 90
|
Percent of subjects exceeding the Carney-Schlauch 95% confidence interval for improvement from baseline in number of words recognized from Consonant-Nucleus-Consonant (CNC) word lists
|
Baseline through Day 90
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Words-in-Noise
Time Frame: Baseline through Day 90
|
Mean absolute percent change in number of recognized words from CNC word lists
|
Baseline through Day 90
|
Standard Pure Tone Audiometry
Time Frame: Baseline through Day 90
|
Mean overall pure tone average (PTA) hearing thresholds in decibels (dB) derived by averaging the air conduction thresholds at 0.5, 1, 2 and 4 kHZ frequencies
|
Baseline through Day 90
|
Patient Global Impression of Change (PGI-C) Hearing Loss Scale
Time Frame: Day 90
|
Average response in PGI-C hearing loss scale, using the assigned numeric values of 1-5: 1) much better, 2) a little better, 3) no change, 4) a little worse 5) much worse
|
Day 90
|
Patient Global Impression of Change (PGI-C) Daily Impacts Scale
Time Frame: Day 90
|
Average response in PGI-C daily impacts scale, using the assigned numeric values of 1-5: 1) much better, 2) a little better, 3) no change, 4) a little worse 5) much worse
|
Day 90
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Carl LeBel, PhD, Frequency Therapeutics
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- FX-322-208
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hearing Loss, Sensorineural
-
Oticon MedicalNot yet recruitingSensorineural Hearing Loss, Bilateral | Sensorineural Hearing Loss, Severe | Sensorineural Hearing Loss, Profound
-
Otologics LLCUnknownMixed Conductive and Sensorineural Hearing Loss, Bilateral
-
CochlearCompletedUnilateral Mixed Conductive and Sensorineural Hearing Loss (Diagnosis) | Sensorineural Hearing Loss, Unilateral With Normal Hearing on the Contralateral SideCanada
-
University College, LondonUnknownSensorineural Hearing Loss | Sensory Hearing Loss | Sensorineural Hearing Loss in Left Ear | Sensorineural Hearing Loss in Right Ear | Sensorineural HearingUnited Kingdom
-
Fundación Pública Andaluza para la gestión de la...RecruitingBilateral Sensorineural Hearing Loss | Unilateral Sensorineural Hearing LossSpain
-
University Hospital, AntwerpCochlearRecruitingHearing Loss, Unilateral | Cochlear Implants | Hearing Loss, Sensorineural, Severe | Hearing Loss, Sensorineural, Bilateral | Hearing Loss, Sensorineural, ProfoundBelgium
-
Auris Medical, Inc.TerminatedHearing Loss, Idiopathic Sudden SensorineuralUnited States, Korea, Republic of, Canada
-
Manchester University NHS Foundation TrustUniversity of ManchesterCompletedCochlear Hearing Loss | Sensorineural Hearing Loss, BilateralUnited Kingdom
-
Cochlear Bone Anchored SolutionsCompletedSingle Sided Sensorineural Deafness | Mixed Hearing Loss, UnilateralDenmark, Spain, United Kingdom, Belgium
-
MED-EL Elektromedizinische Geräte GesmbHCompletedSensorineural Hearing Loss, BilateralFrance
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States